Provided by Tiger Trade Technology Pte. Ltd.

Erasca, Inc.

17.50
-0.5300-2.94%
Volume:36.87K
Turnover:655.39K
Market Cap:6.12B
PE:-18.02
High:17.89
Open:17.87
Low:17.50
Close:18.03
52wk High:24.28
52wk Low:1.33
Shares:349.76M
Float Shares:291.15M
Volume Ratio:0.92
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9710
EPS(LYR):-0.4393
ROE:-78.25%
ROA:-21.39%
PB:16.91
PE(LYR):-39.84

Loading ...

Erasca falls after disclosing patient died after withdrawing from trial

TIPRANKS
·
Apr 28

Top Premarket Decliners

MT Newswires Live
·
Apr 28

BUZZ-U.S. STOCKS ON THE MOVE-UPS, Centene, Coca-Cola

Reuters
·
Apr 28

Analyst Maintains Buy on ERAS-0015’s Promising Early Data, Keeps Price Target Unchanged at $20

TIPRANKS
·
Apr 28

BUZZ-Erasca drops after patient death reported in early cancer trial

Reuters
·
Apr 28

Erasca Shares Down 36.6% Premarket; Co Announces Early-Stage Trial Results for Experimental Cancer Treatment

THOMSON REUTERS
·
Apr 28

Stock Track | Erasca Plunges 34.78% in Pre-market Following Patent Infringement Allegations by Revolution Medicines

Stock Track
·
Apr 28

Stock Track | Erasca Plunges 30.08% in Overnight Trading Following Patent Infringement Allegations by Revolution Medicines

Stock Track
·
Apr 28

24H | Sanmina Surges 14%; Nucor Jumps 5%; Bloom Energy Gains 4%; Nvidia Rises 1%; Celestica Drops 8%; Rambus Sinks 11%

Tiger Newspress
·
Apr 28

Stocks to Watch: Bed Bath & Beyond, Erasca, Simpson Manufacturing, LendingClub

Dow Jones
·
Apr 28

Erasca Shares Tumble, Revolution Medicines Alleges Cancer Drug Patent Infringement

Dow Jones
·
Apr 28

Erasca Reports Encouraging Phase 1 Data for ERAS-0015

TIPRANKS
·
Apr 28

Erasca Inc - Announces Positive Preliminary Phase 1 Data for Eras-0015 in Ras-Mutant Solid Tumors

THOMSON REUTERS
·
Apr 28

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

GlobeNewswire
·
Apr 28

Erasca believes Revolution infringement claims ‘without merit,’ says Stifel

TIPRANKS
·
Apr 27

Mizuho Raises Price Target on Erasca to $28 From $19, Keeps Outperform Rating

MT Newswires Live
·
Apr 27

Erasca Highlights ERAS-0015 Phase 1 Data Update

TIPRANKS
·
Apr 27

Erasca Inc - Revolution Medicines Alleges Trade Secret Misappropriation Related to Eras-0015 - SEC Filing

THOMSON REUTERS
·
Apr 27

Erasca Inc - Revolution Medicines Demands Erasca Cease U.S. Activities for Eras-0015 and Comparative Statements - SEC Filing

THOMSON REUTERS
·
Apr 27

Erasca to discuss preliminary Phase 1 ERAS-0015 dose-escalation data in RAS-mutant tumors

Reuters
·
Apr 27